Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes

Robert H. Eckel, Robert R. Henry, Patrick Yue, Arvinder Dhalla, Pamela Wong, Philip Jochelson, Luiz Belardinelli, Jay S Skyler

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

OBJECTIVE: Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone. RESEARCH DESIGN AND METHODS: The study was conducted worldwide in 465 subjects, with baseline HbA1c of 7-10% (53-86 mmol/mol) and fasting serum glucose of 130-240 mg/dL, randomized to placebo versus ranolazine. RESULTS: Compared with placebo, there was a greater decline in HbA1c at week 24 from baseline (primary end point) in subjects taking ranolazine (mean difference -0.56% [-6.1 mmol/mol]; P <0.0001). Moreover, the proportion of subjects achieving an HbA1c 1c and other measures of glycemic control.

Original languageEnglish (US)
Pages (from-to)1189-1196
Number of pages8
JournalDiabetes Care
Volume38
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Type 2 Diabetes Mellitus
Placebos
Glycosylated Hemoglobin A
Ranolazine
Life Style
Fasting
Research Design
Sodium
Safety
Glucose
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Eckel, R. H., Henry, R. R., Yue, P., Dhalla, A., Wong, P., Jochelson, P., ... Skyler, J. S. (2015). Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care, 38(7), 1189-1196. https://doi.org/10.2337/dc14-2629

Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. / Eckel, Robert H.; Henry, Robert R.; Yue, Patrick; Dhalla, Arvinder; Wong, Pamela; Jochelson, Philip; Belardinelli, Luiz; Skyler, Jay S.

In: Diabetes Care, Vol. 38, No. 7, 01.07.2015, p. 1189-1196.

Research output: Contribution to journalArticle

Eckel, RH, Henry, RR, Yue, P, Dhalla, A, Wong, P, Jochelson, P, Belardinelli, L & Skyler, JS 2015, 'Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes', Diabetes Care, vol. 38, no. 7, pp. 1189-1196. https://doi.org/10.2337/dc14-2629
Eckel RH, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P et al. Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care. 2015 Jul 1;38(7):1189-1196. https://doi.org/10.2337/dc14-2629
Eckel, Robert H. ; Henry, Robert R. ; Yue, Patrick ; Dhalla, Arvinder ; Wong, Pamela ; Jochelson, Philip ; Belardinelli, Luiz ; Skyler, Jay S. / Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. In: Diabetes Care. 2015 ; Vol. 38, No. 7. pp. 1189-1196.
@article{17ca60ead5784510a367fa46f4fd1708,
title = "Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes",
abstract = "OBJECTIVE: Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone. RESEARCH DESIGN AND METHODS: The study was conducted worldwide in 465 subjects, with baseline HbA1c of 7-10{\%} (53-86 mmol/mol) and fasting serum glucose of 130-240 mg/dL, randomized to placebo versus ranolazine. RESULTS: Compared with placebo, there was a greater decline in HbA1c at week 24 from baseline (primary end point) in subjects taking ranolazine (mean difference -0.56{\%} [-6.1 mmol/mol]; P <0.0001). Moreover, the proportion of subjects achieving an HbA1c 1c and other measures of glycemic control.",
author = "Eckel, {Robert H.} and Henry, {Robert R.} and Patrick Yue and Arvinder Dhalla and Pamela Wong and Philip Jochelson and Luiz Belardinelli and Skyler, {Jay S}",
year = "2015",
month = "7",
day = "1",
doi = "10.2337/dc14-2629",
language = "English (US)",
volume = "38",
pages = "1189--1196",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes

AU - Eckel, Robert H.

AU - Henry, Robert R.

AU - Yue, Patrick

AU - Dhalla, Arvinder

AU - Wong, Pamela

AU - Jochelson, Philip

AU - Belardinelli, Luiz

AU - Skyler, Jay S

PY - 2015/7/1

Y1 - 2015/7/1

N2 - OBJECTIVE: Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone. RESEARCH DESIGN AND METHODS: The study was conducted worldwide in 465 subjects, with baseline HbA1c of 7-10% (53-86 mmol/mol) and fasting serum glucose of 130-240 mg/dL, randomized to placebo versus ranolazine. RESULTS: Compared with placebo, there was a greater decline in HbA1c at week 24 from baseline (primary end point) in subjects taking ranolazine (mean difference -0.56% [-6.1 mmol/mol]; P <0.0001). Moreover, the proportion of subjects achieving an HbA1c 1c and other measures of glycemic control.

AB - OBJECTIVE: Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone. RESEARCH DESIGN AND METHODS: The study was conducted worldwide in 465 subjects, with baseline HbA1c of 7-10% (53-86 mmol/mol) and fasting serum glucose of 130-240 mg/dL, randomized to placebo versus ranolazine. RESULTS: Compared with placebo, there was a greater decline in HbA1c at week 24 from baseline (primary end point) in subjects taking ranolazine (mean difference -0.56% [-6.1 mmol/mol]; P <0.0001). Moreover, the proportion of subjects achieving an HbA1c 1c and other measures of glycemic control.

UR - http://www.scopus.com/inward/record.url?scp=84944356404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944356404&partnerID=8YFLogxK

U2 - 10.2337/dc14-2629

DO - 10.2337/dc14-2629

M3 - Article

C2 - 26049552

AN - SCOPUS:84944356404

VL - 38

SP - 1189

EP - 1196

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 7

ER -